Immobilized Unconjugated GLP-1R His&Avi Tag, Human (Cat. No. UA016019) at 1.0μg/mL (100μL/well) can bind Anti-Gulgafafusp alfa Monoclonal Antibody (Glutazumab) (Cat. No. UA016034) with EC50 of 0.72-0.90 ng/mL.
Anti-Gulgafafusp alfa Monoclonal Antibody (Glutazumab)
Anti-Gulgafafusp alfa Monoclonal Antibody (Glutazumab)
Price:
Regular price
$285 USD
Regular price
Sale price
$285 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | Gulgafafusp alfa |
| Antibody Type | Recombinant mAb |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
Gulgafafusp alfa is a humanized IgG2κ monoclonal antibody fusion protein targeting the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus and obesity. This protein is engineered through genetic fusion of a GLP-1(7-35) agonist fragment to the Fc region of an anti-GLP-1R antibody, forming a unique "antibody-ligand" bifunctional structure: the antibody moiety specifically binds to GLP-1R, while the GLP-1 fragment activates downstream cAMP signaling pathways. Through synergistic dual receptor binding sites, this design significantly enhances binding affinity and prolongs half-life. As a long-acting GLP-1R agonist, Gulgafafusp alfa promotes glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and increases satiety, thereby achieving sustained glycemic control and weight reduction effects.
Picture
Picture
ELISA
